The Medicines Intelligence Data Platform: A Population-Based Data Resource From New South Wales, Australia.

IF 2.4 4区医学 Q3 PHARMACOLOGY & PHARMACY

Pharmacoepidemiology and Drug Safety Pub Date : 2024-08-01 DOI:10.1002/pds.5887

Helga Zoega, Michael O Falster, Malcolm B Gillies, Melisa Litchfield, Ximena Camacho, Claudia Bruno, Benjamin Daniels, Natasha Donnolley, Alys Havard, Andrea L Schaffer, Georgina Chambers, Louisa Degenhardt, Timothy Dobbins, Natasa Gisev, Rebecca Ivers, Louisa Jorm, Bette Liu, Claire M Vajdic, Sallie-Anne Pearson

{"title":"The Medicines Intelligence Data Platform: A Population-Based Data Resource From New South Wales, Australia.","authors":"Helga Zoega, Michael O Falster, Malcolm B Gillies, Melisa Litchfield, Ximena Camacho, Claudia Bruno, Benjamin Daniels, Natasha Donnolley, Alys Havard, Andrea L Schaffer, Georgina Chambers, Louisa Degenhardt, Timothy Dobbins, Natasa Gisev, Rebecca Ivers, Louisa Jorm, Bette Liu, Claire M Vajdic, Sallie-Anne Pearson","doi":"10.1002/pds.5887","DOIUrl":null,"url":null,"abstract":"Background: The Medicines Intelligence (MedIntel) Data Platform is an anonymised linked data resource designed to generate real-world evidence on prescribed medicine use, effectiveness, safety, costs and cost-effectiveness in Australia.Results: The platform comprises Medicare-eligible people who are ≥18 years and residing in New South Wales (NSW), Australia, any time during 2005-2020, with linked administrative data on dispensed prescription medicines (Pharmaceutical Benefits Scheme), health service use (Medicare Benefits Schedule), emergency department visits (NSW Emergency Department Data Collection), hospitalisations (NSW Admitted Patient Data Collection) plus death (National Death Index) and cancer registrations (NSW Cancer Registry). Data are currently available to 2022, with approval to update the cohort and data collections annually. The platform includes 7.4 million unique people across all years, covering 36.9% of the Australian adult population; the overall population increased from 4.8 M in 2005 to 6.0 M in 2020. As of 1 January 2019 (the last pre-pandemic year), the cohort had a mean age of 48.7 years (51.1% female), with most people (4.4 M, 74.7%) residing in a major city. In 2019, 4.4 M people (73.3%) were dispensed a medicine, 1.2 M (20.5%) were hospitalised, 5.3 M (89.4%) had a GP or specialist appointment, and 54 003 people died. Anti-infectives were the most prevalent medicines dispensed to the cohort in 2019 (43.1%), followed by nervous system (32.2%) and cardiovascular system medicines (30.2%).Conclusion: The MedIntel Data Platform creates opportunities for national and international research collaborations and enables us to address contemporary clinically- and policy-relevant research questions about quality use of medicines and health outcomes in Australia and globally.","PeriodicalId":19782,"journal":{"name":"Pharmacoepidemiology and Drug Safety","volume":"33 8","pages":"e5887"},"PeriodicalIF":2.4000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacoepidemiology and Drug Safety","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/pds.5887","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The Medicines Intelligence (MedIntel) Data Platform is an anonymised linked data resource designed to generate real-world evidence on prescribed medicine use, effectiveness, safety, costs and cost-effectiveness in Australia.

Results: The platform comprises Medicare-eligible people who are ≥18 years and residing in New South Wales (NSW), Australia, any time during 2005-2020, with linked administrative data on dispensed prescription medicines (Pharmaceutical Benefits Scheme), health service use (Medicare Benefits Schedule), emergency department visits (NSW Emergency Department Data Collection), hospitalisations (NSW Admitted Patient Data Collection) plus death (National Death Index) and cancer registrations (NSW Cancer Registry). Data are currently available to 2022, with approval to update the cohort and data collections annually. The platform includes 7.4 million unique people across all years, covering 36.9% of the Australian adult population; the overall population increased from 4.8 M in 2005 to 6.0 M in 2020. As of 1 January 2019 (the last pre-pandemic year), the cohort had a mean age of 48.7 years (51.1% female), with most people (4.4 M, 74.7%) residing in a major city. In 2019, 4.4 M people (73.3%) were dispensed a medicine, 1.2 M (20.5%) were hospitalised, 5.3 M (89.4%) had a GP or specialist appointment, and 54 003 people died. Anti-infectives were the most prevalent medicines dispensed to the cohort in 2019 (43.1%), followed by nervous system (32.2%) and cardiovascular system medicines (30.2%).

Conclusion: The MedIntel Data Platform creates opportunities for national and international research collaborations and enables us to address contemporary clinically- and policy-relevant research questions about quality use of medicines and health outcomes in Australia and globally.

查看原文本刊更多论文

药品情报数据平台：澳大利亚新南威尔士州基于人口的数据资源。

背景：药品情报（MedIntel）数据平台是一个匿名链接数据资源，旨在生成有关澳大利亚处方药使用、有效性、安全性、成本效益的真实证据：药物情报（MedIntel）数据平台是一个匿名链接数据资源，旨在生成有关澳大利亚处方药使用、有效性、安全性、成本和成本效益的真实证据：该平台包括 2005-2020 年间任何时候居住在澳大利亚新南威尔士州（NSW）、年龄≥18 岁、符合医疗保险资格的人，其链接管理数据包括处方药配发（药品福利计划）、医疗服务使用（医疗保险福利表）、急诊就诊（新南威尔士州急诊科数据收集）、住院（新南威尔士州住院病人数据收集）以及死亡（国家死亡指数）和癌症登记（新南威尔士州癌症登记）。目前可提供至 2022 年的数据，并获准每年更新队列和数据收集。该平台包括所有年份的 740 万独特人口，覆盖澳大利亚成年人口的 36.9%；总人口从 2005 年的 480 万增加到 2020 年的 600 万。截至 2019 年 1 月 1 日（大流行前的最后一年），群组的平均年龄为 48.7 岁（51.1% 为女性），大多数人（440 万人，74.7%）居住在大城市。2019 年，440 万人（73.3%）获得了药品，120 万人（20.5%）住院治疗，530 万人（89.4%）预约了全科医生或专科医生，54003 人死亡。2019年，抗感染药物是组群中配发最多的药物（43.1%），其次是神经系统药物（32.2%）和心血管系统药物（30.2%）：MedIntel数据平台为国内和国际研究合作创造了机会，使我们能够解决有关澳大利亚和全球药品使用质量和健康结果的当代临床和政策相关研究问题。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pharmacoepidemiology and Drug Safety 医学-药学

CiteScore

4.80

自引率

7.70%

发文量

173

审稿时长

3 months

期刊介绍： The aim of Pharmacoepidemiology and Drug Safety is to provide an international forum for the communication and evaluation of data, methods and opinion in the discipline of pharmacoepidemiology. The Journal publishes peer-reviewed reports of original research, invited reviews and a variety of guest editorials and commentaries embracing scientific, medical, statistical, legal and economic aspects of pharmacoepidemiology and post-marketing surveillance of drug safety. Appropriate material in these categories may also be considered for publication as a Brief Report. Particular areas of interest include: design, analysis, results, and interpretation of studies looking at the benefit or safety of specific pharmaceuticals, biologics, or medical devices, including studies in pharmacovigilance, postmarketing surveillance, pharmacoeconomics, patient safety, molecular pharmacoepidemiology, or any other study within the broad field of pharmacoepidemiology; comparative effectiveness research relating to pharmaceuticals, biologics, and medical devices. Comparative effectiveness research is the generation and synthesis of evidence that compares the benefits and harms of alternative methods to prevent, diagnose, treat, and monitor a clinical condition, as these methods are truly used in the real world; methodologic contributions of relevance to pharmacoepidemiology, whether original contributions, reviews of existing methods, or tutorials for how to apply the methods of pharmacoepidemiology; assessments of harm versus benefit in drug therapy; patterns of drug utilization; relationships between pharmacoepidemiology and the formulation and interpretation of regulatory guidelines; evaluations of risk management plans and programmes relating to pharmaceuticals, biologics and medical devices.